BR112019010139A2 - polipeptídeos biespecíficos para gitr e ctla-4 - Google Patents
polipeptídeos biespecíficos para gitr e ctla-4Info
- Publication number
- BR112019010139A2 BR112019010139A2 BR112019010139A BR112019010139A BR112019010139A2 BR 112019010139 A2 BR112019010139 A2 BR 112019010139A2 BR 112019010139 A BR112019010139 A BR 112019010139A BR 112019010139 A BR112019010139 A BR 112019010139A BR 112019010139 A2 BR112019010139 A2 BR 112019010139A2
- Authority
- BR
- Brazil
- Prior art keywords
- gitr
- ctla
- bispecific polypeptides
- polypeptides
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
a presente invenção fornece polipeptídeos multiespecíficos, tais como anticorpos biespecíficos, compreendendo um primeiro domínio de ligação capaz de se ligar especificamente a gitr e um segundo domínio de ligação capaz de se ligar especificamente a ctla-4. a invenção proporciona ainda composições dos ditos polipeptídeos biespecíficos, bem como métodos e utilizações dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1619652.9A GB201619652D0 (en) | 2016-11-21 | 2016-11-21 | Novel polypeptides |
PCT/EP2017/079925 WO2018091739A1 (en) | 2016-11-21 | 2017-11-21 | Bispecific polypeptides to gitr and ctla-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019010139A2 true BR112019010139A2 (pt) | 2019-10-08 |
Family
ID=57993718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019010139A BR112019010139A2 (pt) | 2016-11-21 | 2017-11-21 | polipeptídeos biespecíficos para gitr e ctla-4 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190309084A1 (pt) |
EP (1) | EP3541475A1 (pt) |
JP (1) | JP2019535282A (pt) |
KR (1) | KR20190082235A (pt) |
CN (1) | CN109963621A (pt) |
AU (1) | AU2017360093A1 (pt) |
BR (1) | BR112019010139A2 (pt) |
CA (1) | CA3044345A1 (pt) |
GB (1) | GB201619652D0 (pt) |
IL (1) | IL266765A (pt) |
MX (1) | MX2019005933A (pt) |
RU (1) | RU2019116638A (pt) |
WO (1) | WO2018091739A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200041835A (ko) * | 2017-09-01 | 2020-04-22 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 재조합 이중특이적 항체 |
WO2020028269A2 (en) * | 2018-07-30 | 2020-02-06 | Invenra Inc. | Multispecific treg binding molecules |
EP3831849A1 (en) * | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
DK1776384T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
CA2936611A1 (en) * | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
SG11201610074YA (en) * | 2014-06-06 | 2016-12-29 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
EP3789399A1 (en) * | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
CN105669867A (zh) * | 2014-11-21 | 2016-06-15 | 上海中信国健药业股份有限公司 | 抗gitr/ctla-4双特异性抗体及其制备方法和用途 |
MX2017014699A (es) | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Polipeptidos novedosos. |
-
2016
- 2016-11-21 GB GBGB1619652.9A patent/GB201619652D0/en not_active Ceased
-
2017
- 2017-11-21 CA CA3044345A patent/CA3044345A1/en not_active Abandoned
- 2017-11-21 MX MX2019005933A patent/MX2019005933A/es unknown
- 2017-11-21 EP EP17809226.8A patent/EP3541475A1/en not_active Withdrawn
- 2017-11-21 CN CN201780071259.7A patent/CN109963621A/zh active Pending
- 2017-11-21 KR KR1020197014493A patent/KR20190082235A/ko unknown
- 2017-11-21 BR BR112019010139A patent/BR112019010139A2/pt not_active Application Discontinuation
- 2017-11-21 US US16/461,525 patent/US20190309084A1/en not_active Abandoned
- 2017-11-21 RU RU2019116638A patent/RU2019116638A/ru not_active Application Discontinuation
- 2017-11-21 JP JP2019527250A patent/JP2019535282A/ja active Pending
- 2017-11-21 WO PCT/EP2017/079925 patent/WO2018091739A1/en active Application Filing
- 2017-11-21 AU AU2017360093A patent/AU2017360093A1/en not_active Abandoned
-
2019
- 2019-05-21 IL IL266765A patent/IL266765A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019535282A (ja) | 2019-12-12 |
WO2018091739A1 (en) | 2018-05-24 |
MX2019005933A (es) | 2019-07-08 |
EP3541475A1 (en) | 2019-09-25 |
RU2019116638A (ru) | 2020-12-21 |
GB201619652D0 (en) | 2017-01-04 |
KR20190082235A (ko) | 2019-07-09 |
CA3044345A1 (en) | 2018-05-24 |
US20190309084A1 (en) | 2019-10-10 |
AU2017360093A1 (en) | 2019-06-20 |
IL266765A (en) | 2019-07-31 |
CN109963621A (zh) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005381A2 (es) | Inhibidores éster de acc y usos de los mismos | |
EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
EA201591961A1 (ru) | Ингибиторы акк и их применение | |
EA201591959A1 (ru) | Ингибиторы акк и их применение | |
EA201591960A1 (ru) | Ингибиторы акк и их применение | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
MX2018003196A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
BR112019012342A2 (pt) | anticorpos il-11 | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
PE20170701A1 (es) | Inmunomoduladores | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
TR201905458T4 (tr) | Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri. | |
EA201591962A1 (ru) | Ингибиторы акк и их применение | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
BR112016005957A2 (pt) | detecção de alvo multiaptâmero | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
ECSP17045736A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
BR112019010139A2 (pt) | polipeptídeos biespecíficos para gitr e ctla-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |